Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing - Diversity Supplement

西南部落国家的美洲印第安人参与癌症基因组测序 - Diversity Supplement

• 批准号: 10584299
• 负责人: JEFFREY M. TRENT
• 金额: $ 14.5万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-02 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10584299
• 关键词: Address; Affect; Age; American Indians; Cancer Patient; Communities; Data Set; Databases; Death Rate; Diagnosis; Disease Outcome; Ethnic group; Genes; Genetic Research; Genetic Transcription; Genomics; Goals; Hispanic; Incidence; Malignant Neoplasms; Molecular; Mutation; Not Hispanic or Latino; Outcome; Pathogenesis; Pathway interactions; Population; Precision Medicine Initiative; Race; Renal Cell Carcinoma; Research; Sampling; Techniques; Translating; United States; cancer genome; cancer type; driver mutation; genome sequencing; health disparity; improved; insight; personalized medicine; precision medicine; targeted treatment; transcriptome sequencing; tribal Nation; tumor

Project Summary Cancer incidence and associated death rates affecting American Indian (AI) communities are significantly higher than other races in the United States. More specifically, renal cell carcinoma (RCC) is the most common form of cancer in AI populations with diagnoses occurring at a younger age when compared to other races. Current sequencing datasets that are used for improving personalized medicine lacks information from AI cancer samples due to the lack of AI involvement in genomic and genetic research. Our ultimate goal for this project is to translate our findings to improve precision medicine for all populations, understanding the unique causes and driver mutations in AI cancer patients is a necessity. We hypothesize that functionally relevant and unique mutational signatures and molecular pathway disruption exist in the AI cancer samples and their identification will provide significant insights into cancer pathogenesis, progression, and will also help to improve diagnoses and treatment. To address this hypothesis, we propose the following aims; 1). compare mutational signatures identified in renal cell carcinoma (RCC) in AI to Hispanic and non-Hispanic White tumor samples, and 2). determine transcriptional pathway disruption in AI RCC and compare to Hispanic and non- Hispanic White using RNA sequencing techniques. This project will be crucial in bridging the gap between precision medicine and AI cancer outcomes by identifying disrupted genes and molecular pathways and will help to identify targets for therapeutic management and improving the disease outcome in these communities thereby reducing RCC health disparities.

项目摘要 影响美国印第安人（AI）社区的癌症发病率和相关死亡率显着增加。 高于美国其他种族。更具体地说，肾细胞癌（RCC）是最常见的癌症。 AI人群中常见的癌症形式，与其他癌症相比，诊断发生在更年轻的年龄 种族目前用于改善个性化医疗的测序数据集缺乏来自以下方面的信息： AI癌症样本由于缺乏AI参与基因组和遗传研究。我们的最终目标是 该项目旨在将我们的发现转化为改善所有人群的精准医学，了解 AI癌症患者的独特原因和驱动突变是必要的。我们假设在功能上 AI癌症样本中存在相关且独特的突变特征和分子途径破坏 它们的鉴定将为癌症的发病机制、进展提供重要的见解， 有助于改善诊断和治疗。为了解决这个问题，我们提出了以下目标：（1）。 比较AI与西班牙裔和非西班牙裔肾细胞癌（RCC）中鉴定的突变特征 白色肿瘤样品，和2）。确定AI RCC中的转录途径破坏，并与 西班牙裔和非西班牙裔白色人使用RNA测序技术。这个项目将是至关重要的桥梁 通过识别被破坏的基因和分子，精确医学和AI癌症结果之间的差距 途径，并将有助于确定治疗管理的目标，并改善疾病的结果， 这些社区，从而减少RCC的健康差距。